NCT06999278 (LIGHT) is a Phase 3 clinical trial of Levothyroxin in Abortion, Habitual, sponsored by Women's Hospital School Of Medicine Zhejiang University.

Who is sponsoring NCT06999278?

NCT06999278 is sponsored by Women's Hospital School Of Medicine Zhejiang University.

What drugs are being tested in NCT06999278?

Interventions in NCT06999278: Levothyroxin, Placebo.

What condition does NCT06999278 study?

NCT06999278 studies Abortion, Habitual.

Is NCT06999278 still recruiting?

NCT06999278 is currently not yet recruiting. Last updated 4 June 2025.

Last reviewed 2025-06-04 · How we verify

NCT06999278: LIGHT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

LIGHT Trial: Levothyroxine for Gestational Hypothyroidism in Recurrent Pregnancy Loss

Not yet recruiting Phase 3 Last updated 4 June 2025

What this trial tests

Phase 3 trial testing Levothyroxin in Abortion, Habitual in 200 participants. Not yet recruiting.

Timeline

1 June 2025

Primary endpoint
30 April 2027

31 May 2027

Quick facts

Lead sponsor	Women's Hospital School Of Medicine Zhejiang University
Phase	Phase 3
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	200
Start date	1 June 2025
Primary completion	30 April 2027
Estimated completion	31 May 2027
Sites	2 locations across China

Drugs / interventions tested

Levothyroxin — full drug profile →
Placebo

Conditions studied

Abortion, Habitual — all drugs for Abortion, Habitual →

Sponsor

Women's Hospital School Of Medicine Zhejiang University

Who can join

Adults 18 to 40, female only, with Abortion, Habitual. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this randomized, double-blind, placebo-controlled clinical trial is to evaluate whether levothyroxine supplement improves pregnancy outcomes in women with recurrent pregnancy loss (RPL) and isolated maternal hypothyroidism (IMH). The main questions it aims to answer are: Does levothyroxine increase the live birth rate after 24 weeks of gestation? Does levothyroxine improve secondary outcomes such as ongoing pregnancy rates, reduce the incidence of pregnancy loss, or influence maternal and neonatal complications? Researchers will: Compare the levothyroxine treatment group (50 µg/day) to the placebo group to assess the impact of the intervention on live birth rates and other pregnancy outcomes. Participants will: Be randomly assigned to receive either levothyroxine or a placebo. Take the assigned treatment daily starting from enrollment until the end of pregnancy. Undergo routine follow-up visits to monitor pregnancy progress and outcomes. This trial seeks to determine whether routine levothyroxine supplementation can improve pregnancy outcomes for women with RPL and IMH.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Levothyroxin

Trials testing the same drug.

NCT06971965 — Necessity of TSH Suppression Therapy in Active Surveillance for Thyroid Cancer Patients. · NA · not yet recruiting
NCT06276205 — Vitamin D & Levothyroxine Combination Versus Levothyroxine on Lipid Profile in Hypothyroidism · Phase 3 · completed
NCT06527859 — Correlation Between Levothyroxine and Blood Th17/Treg in Pregnant Women With Normal-high TSH and Positive TPOAb · terminated
NCT04734457 — Final Height in Patients With CH Diagnosed by the Screening · unknown
NCT06547242 — Levothyroxine-sodium Bioequivalence Trial With Oral Single Dose Administration · Phase 1 · completed

Other Women's Hospital School Of Medicine Zhejiang University trials

Trials by the same sponsor.

NCT07369986 — Immunotherapy for Surgery Avoidance in Vulnerable dMMR Endometrial Cancer · Phase 2 · not yet recruiting
NCT07244965 — Neoadjuvant Ivonescimab Plus Chemotherapy Followed by Concurrent Chemoradiotherapy in High-Risk Locally Advanced Cervica · Phase 2 · not yet recruiting
NCT06561308 — Clinical Efficacy Study of PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Advanced Endometrial Cancer · Phase 2 · recruiting
NCT07106853 — Prenatal Cell-free DNA Screening in Pregnancies With Diverse Genetic Risk Profiles Utilizing Targeted and Whole-exome Se · not yet recruiting
NCT07082530 — A RCT of Labor Induction at 39 Weeks in Low - Risk Women in China · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06999278 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Women's Hospital School Of Medicine Zhejiang University
Last refreshed: 4 June 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06999278.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing